Pricing Log in Create free account
Saturday 17 October 2026 Export ALGS’s income statement to Excel — free account

Aligos Therapeutics, Inc.

ALGS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 2,778.6%, EPS grew 90.9% and free cash flow fell 59.8%, each against the same quarter a year earlier.

4.86 0.53 −9.83%
Market cap
$33.7M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
3/9
Altman Z
−11.00
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 53.50%

Capital & Financial Ratios $m

Market Cap 33.66
Revenue 31.52
Net Income (75.96)
Free Cash Flow (94.52)
Net Debt (30.42)
Current Ratio 2.19 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.70) (negative: loss-making)
P/S ratio 1.61
P/B ratio 1.59
Past 5Y EPS Growth —
This Y EPS Growth (157.06%) (below 0%: weak)
Next Y EPS Growth 17.79% (at or above 15%: strong)
Next Y revenue growth 1,546.39% (at or above 10%: strong)
Next 5Y EPS Growth 0.01%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.6×, against a ten-year median of −3.4×; over the ten years it ranged from −28.6× in 2025 to 64.8× in 2021.
P/S against its own 10 years 1.91%
10-year low 10-year high
P/B against its own 10 years 65.95%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 136 57 78 30
Receivables — — — 28
Inventory — — — —
Other 5 5 5 4
141 62 83 62
2023 2024 2025 Q'26
Payables 3 3 4 6
ST’ Debt — — — —
Other — — — —
24 22 21 28

Compound Annual Growth %

10y 5y 3y
Sales — — (46.03%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (24.62%) (19.83%)

Revenue $m

Mar Jun Sep Dec Year
’26 3 28 — — —
’25 0 1 1 0 2
’24 1 1 1 1 4
’23 3 7 3 3 16
’22 3 4 4 4 14
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (25) — — —
’25 (21) (16) (24) (22) (83)
’24 (23) (19) (20) (18) (81)
’23 (22) (14) (20) (23) (79)
’22 (20) (25) (17) (17) (79)
’21 (30) (23) (25) (37) (116)
’20 (20) (18) (17) (20) (74)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (25) — — —
’25 (21) (16) (25) (22) (83)
’24 (23) (19) (20) (18) (81)
’23 (22) (14) (20) (23) (79)
’22 (21) (25) (17) (17) (80)
’21 (30) (23) (25) (38) (117)
’20 (21) (18) (17) (20) (76)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.21) (0.14) — — —
’25 4.95 (1.53) (3.04) (1.91) (2.45)
’24 (5.50) 0.75 (3.07) (13.08) (20.94)
’23 (13.25) (10.75) (10.25) (5.50) (34.00)
’22 (21.00) (11.75) (11.00) (12.75) (56.25)
’21 (18.50) (19.75) (19.50) (22.25) (80.50)
’20 (189.02) (184.96) (274.91) (27.25) (271.75)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 320.50 277.75 21.00 13.48 6.76 3.76

Analyst estimates 2026–2028

Powerpack
High — — — — 891.75 937.75 312.00 60.25 44.39 46.80
People
People Employees — — — 67 74 93 83 66 70 82
Revenue/emp, $m — — — 0.00 0.00 0.05 0.17 0.24 0.06 0.03
Income, $m
Income, $m Revenue — — — — — 4 14 16 4 2
Gross margin, % — — 0.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00
EBT — — (14) (52) (108) (128) (96) (87) (131) (24)
EBT margin, % — — 0.00 0.00 0.00 (2,940.79) (689.87) (559.50) (3,317.62) (1,092.36)
Net income — 0 (14) (52) (109) (128) (96) (88) (131) (24)
Depreciation — — 2 1 4 4 4 3 (1) (1)
Per share, $
Per share, $ Revenue — — 0.00 0.00 0.00 2.73 8.14 6.06 0.63 0.22
Earnings — — (292.22) (651.02) (271.75) (80.50) (56.25) (34.00) (20.94) (2.45)
Cash flow — — (126.81) (582.40) (185.89) (72.55) (46.49) (30.82) (12.89) (8.35)
Capex — — (52.75) (34.69) (5.17) (0.56) (0.55) (0.01) (0.02) (0.04)
Free cash flow — — (179.56) (617.10) (191.06) (73.11) (47.04) (30.83) (12.91) (8.39)
Book value — — (288.22) (808.11) 550.79 115.88 60.84 35.93 (4.62) 5.42
Shares, m — — 0 0 0 2 2 3 6 10
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.00 0.00
P/S — — — — — 108.53 2.89 2.93 63.27 42.14
P/B — — — — — 2.56 0.39 0.49 0.00 1.72
EV/Sales — — — — — 64.80 (6.15) (5.80) 48.84 6.54
EV/FCF — — — — — (2.42) 1.07 1.14 (2.38) (0.17)
Cash, $m
Cash, $m Operating cash flow — — (6) (47) (74) (116) (79) (79) (81) (83)
Capex — — (3) (3) (2) (1) (1) 0 0 0
Free cash flow — — (9) (50) (76) (117) (80) (79) (81) (83)
Balance, $m
Balance, $m Working capital — — 85 106 220 165 100 117 40 62
Total debt — — 0 0 0 0 0 0 0 —
Net debt — — (91) (118) (244) (191) (126) (136) (57) (78)
Shareholders’ equity — — (14) (65) 220 185 104 92 (29) 54
Returns, %
Returns, % ROA — — (25.87) (41.11) (52.71) (51.26) (50.28) (58.80) (118.41) (30.50)
ROIC — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE — — 35.44 132.92 (139.92) (63.41) (66.55) (89.48) (415.84) (196.92)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Aligos Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NNVC NanoViricides, Inc. $35.0M — (loss-making) — — n/m −23.94% (below 0%: shrinking) 0.00% 0.00% Compare
LIANY LianBio Sponsored ADR $34.2M 0.0× — — n/m +1,107.59% (above 0%: growing) 0.00% 0.00% Compare
CRVO CervoMed Inc. $34.0M — (loss-making) — (loss-making) −99.60% (below 0%: shrinking) n/m −6.20% (below 0%: shrinking) 100.00% 0.00% Compare
IRLA Quince Therapeutics, Inc. $33.8M — (loss-making) — — n/m −63.65% (below 0%: shrinking) 0.00% 0.00% Compare
ALGS Aligos Therapeutics, Inc. $33.7M — (loss-making) — (loss-making) +2,778.55% (above 0%: growing) n/m −59.81% (below 0%: shrinking) 100.00% (6.80%)
ATNM Actinium Pharmaceuticals, Inc. $33.3M 3.1× — (loss-making) +77,677.78% (above 0%: growing) n/m −4.91% (below 0%: shrinking) 100.00% 78.76% Compare
BCTX BRIACELL THERAP $32.8M 1.5× — — n/m +0.21% (above 0%: growing) 0.00% 0.00% Compare
GNTA Genenta Science S.p.A. Unsponsored ADR $32.3M — — — — +35.94% (above 0%: growing) 0.00% — Compare
MGX Metagenomi Therapeutics, Inc. $31.9M — (loss-making) — (loss-making) −103.02% (below 0%: shrinking) n/m +7.98% (above 0%: growing) 100.00% 11,195.72% Compare
Median of peers $33.6M 1.5× — −99.60% — −2.35% 0.00% 0.00%

All 614 Biotechnology stocks →

Aligos Therapeutics, Inc. (ALGS) key facts

  • Aligos Therapeutics, Inc. (ALGS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ALGS traded at $4.86, a market capitalization of $33.7 million.
  • Return on equity was −196.9% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −11.00 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Aligos Therapeutics, Inc. (ALGS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ALGS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com